The World Anti-Doping Agency has signed RTP-based GlaxoSmithKline to help detect banned substances in sports.
In 2011, GSK signed an agreement with WADA to help identify doping compounds in the early stage.
Under the new agreement, GSK scientists will identify substances with a probable or high risk of abuse in sports.
“Our work with the pharmaceutical industry is critical to staying one step ahead of the dopers, who have an ever increasing level of scientific expertise,” said WADA President John Fahey in a written release. “We are delighted to be entering into this partnership with GSK as it will play a significant role in helping WADA achieve its mission of a doping free sporting culture.”
Several drug makers have committed to signing similar agreements with WADA.